Atara Biotherapeutics Inc (NASDAQ:ATRA) shares, rose in value, with the stock price up by 8.18% to the previous day’s close as strong demand from buyers drove the stock to $0.78.
Actively observing the price movement in the last trading, the stock closed the session at $0.72. Referring to stock’s 52-week performance, its high was $3.08, and the low was $0.20. On the whole, ATRA has fluctuated by 12.64% over the past month.
With the market capitalization of Atara Biotherapeutics Inc currently standing at about $92.97 million, investors are eagerly awaiting this quarter’s results, scheduled for May 06, 2024 – May 10, 2024. As a result, investors might want to see an improvement in the stock’s price before the company announces its earnings report. Analysts are projecting the company’s earnings per share (EPS) to be -$0.32, which is expected to increase to -$0.03 for fiscal year -$1.06 and then to about -$0.55 by fiscal year 2025. Data indicates that the EPS growth is expected to be 59.40% in 2025, while the next year’s EPS growth is forecast to be 48.10%.
Analysts have estimated the company’s revenue for the quarter at $21.92 million, with a low estimate of $3.9 million and a high estimate of $41.27 million. According to the average forecast, sales growth in current quarter could jump up 1,687.90%, compared to the corresponding quarter of last year. Wall Street analysts also predicted that in 2025, the company’s y-o-y revenues would reach $91.32 million, representing an increase of 965.20% from the revenues reported in the last year’s results.
Revisions could be a useful indicator to get insight on short-term price movement; so for the company, there were 1 upward and no downward review(s) in last seven days. We see that ATRA’s technical picture suggests that short-term indicators denote the stock is a Hold on average. However, medium term indicators have put the stock in the category of Hold while long term indicators on average have been pointing out that it is a 50% Sell.
The stock’s technical analysis shows that the PEG ratio is about 0, with the price of ATRA currently trading nearly 13.20% and 4.52% away from the simple moving averages for 20 and 50 days respectively. The Relative Strength Index (RSI, 14) currently indicates a reading of 57.89, while the 7-day volatility ratio is showing 9.94% which for the 30-day chart, stands at 10.60%. Furthermore, Atara Biotherapeutics Inc (ATRA)’s beta value is 0.71, and its average true range (ATR) is 0.08.
A comparison of Atara Biotherapeutics Inc (ATRA) with its peers suggests the former has fared considerably weaker in the market. ATRA showed an intraday change of 8.18% in last session, and over the past year, it shrunk by -73.51%%.
Data on historical trading for Atara Biotherapeutics Inc (NASDAQ:ATRA) indicates that the trading volumes over the past 10 days have averaged 1.3 million and over the past 3 months, they’ve averaged 3.08 million. According to company’s latest data on outstanding shares, there are 119.36 million shares outstanding.
Nearly 7.14% of Atara Biotherapeutics Inc’s shares belong to company insiders and institutional investors own 60.75% of the company’s shares. The data on short interest also indicates that stock shorts accounted for 11.03 million shares as on Mar 15, 2024, resulting in a short ratio of 4.32. According to the data, the short interest in Atara Biotherapeutics Inc (ATRA) stood at 10.82% of shares outstanding as of Mar 15, 2024; the number of short shares registered in Feb 15, 2024 reached 10.87 million. The stock has risen by 51.89% since the beginning of the year, thereby showing the potential of a further growth. This could raise investors’ confidence to be optimistic about the ATRA stock heading into the next quarter.
